Cardio Diagnostics Holdings Granted Innovative Technology Contract from Vizient for AI-Powered Heart Disease Tests Epi+Gen CHD & PrecisionCHD
Wednesday, November 01, 2023
Cardio Diagnostics Holdings, a pioneer in AI-driven precision cardiovascular medicine tests, has announced that its AI-powered molecular heart disease tests, capable of identifying objective epigenetic and genetic biomarkers in individuals suspected of being at risk for or already having coronary heart disease, have secured an Innovative Technology contract from Vizient, Inc. Vizient, the largest provider-driven healthcare performance improvement company in the United States, serves a wide customer base, including over 60% of hospitals and 97% of academic medical centers.
Through this agreement, Cardio Diagnostics' cutting-edge tests will be accessible to Vizient provider customers at negotiated pricing, thereby expanding access to the next generation of cardiovascular disease diagnostics.Cardio Diagnostics' Epi+Gen CHD and PrecisionCHD tests make use of a proprietary AI algorithm for the analysis of objective epigenetic and genetic biomarkers obtained from a patient's blood sample.
The company's innovative approach, combining artificial intelligence with DNA analysis, lies at the core of its groundbreaking technology. These highly sensitive tests can identify patients at risk of developing coronary heart disease or those already afflicted with it, through a simple blood test that can be conveniently conducted remotely or within healthcare provider settings.